Dr. Joshua H. Bilenker, founder of Loxo Oncology, Inc., was CEO of Loxo at Lily from December 2019 through January 2021 and Loxo’s President and Chief Executive Officer from July 2013 until its acquisition by Eli Lilly in February 2019. Dr. Bilenker joined Aisling Capital LLC, an investment firm, in April 2006 and has served as an Operating Partner since November 2013. From 2004 to 2006, Dr. Bilenker served as a Medical Officer at the FDA in the Office of Oncology. Dr. Bilenker also is a member of the board of directors of Sana Biotechnology. Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his A.B. degree in English from Princeton University.